Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2024 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
GRCE on Nasdaq
Shares outstanding
16,654,455
Price per share
$3.51
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
4,327,617
Total reported value
$14,995,992
% of total 13F portfolios
0%
Share change
+620,790
Value change
+$2,269,248
Number of holders
22
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ADAR1 Capital Management, LLC 9.9% $5,836,720 1,648,791 ADAR1 Capital Management GP, LLC 31 Dec 2025
Nantahala Capital Management, LLC 10% 0% $5,616,773 +$646,500 1,586,659 +13% Nantahala Capital Management, LLC 31 Dec 2025
HIRSCHMAN ORIN 5.9% -40% $3,157,115 -$1,444,764 907,217 -31% Orin Hirschman 31 Dec 2025

As of 31 Dec 2025, 22 institutional investors reported holding 4,327,617 shares of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE). This represents 26% of the company’s total 16,654,455 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) together control 26% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Nantahala Capital Management, LLC 7.1% 1,178,203 0% 0.24% $4,076,582
AIGH Capital Management LLC 5.4% 907,217 0% 0.93% $3,146,077
ADAR1 Capital Management, LLC 3.9% 641,988 +83% 0.17% $2,221,278
BANK OF AMERICA CORP /DE/ 3% 494,698 0% 0% $1,711,655
VANGUARD GROUP INC 2.5% 423,981 +3.6% 0% $1,479,694
Cerity Partners LLC 2.5% 422,732 0% $1,462,653
RENAISSANCE TECHNOLOGIES LLC 0.78% 129,781 +53% 0% $449,042
CITADEL ADVISORS LLC 0.25% 42,297 +55% 0% $147,617
XTX Topco Ltd 0.18% 30,261 0% $105,611
MORGAN STANLEY 0.15% 25,448 +1277% 0% $88,050
GSA CAPITAL PARTNERS LLP 0.08% 13,774 0% $48,000
Stratos Wealth Partners, LTD. 0.07% 11,182 0% $38,690
NATIONAL BANK OF CANADA /FI/ 0.02% 2,716 0% 0% $9,370
Tower Research Capital LLC (TRC) 0.01% 1,945 +21% 0% $6,730
BNP PARIBAS FINANCIAL MARKETS 0% 600 0% 0% $2,076
ROYAL BANK OF CANADA 0% 543 0% 0% $2,000
Activest Wealth Management 0% 104 0% 0% $360
SBI Securities Co., Ltd. 0% 101 0% 0% $349
Steward Partners Investment Advisory, LLC 0% 41 0% 0% $142
FLAGSHIP HARBOR ADVISORS, LLC 0% 2 0% $7
NBC SECURITIES, INC. 0% 2 0% 0% $6
Federation des caisses Desjardins du Quebec 0% 1 0% 0% $3
SeaCrest Wealth Management, LLC 0% 0 -100% $0
CITIGROUP INC 0% 0 -100% $0
Stonepine Capital Management, LLC 0% 0 -100% $0

Institutional Holders of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 4,327,617 $14,995,992 +$2,269,248 $3.46 22
2025 Q3 3,706,227 $11,033,102 -$328,360 $2.98 20
2025 Q2 3,816,908 $11,344,205 -$607,725 $2.97 20
2025 Q1 4,024,092 $9,168,718 +$4,408,642 $2.28 17
2024 Q4 2,087,877 $7,835,456 +$4,246,540 $3.74 15
2024 Q3 959,571 $2,878,713 +$2,878,713 $3.00 1